Finding · criterion S4
Does an NDC number mean a peptide product is FDA-approved?
No. FDA explicitly states that assignment of an NDC number and inclusion in its directory do not establish product approval.
An identifier answers a narrower question
The National Drug Code is used to identify listed drug products. FDA's directory contains information submitted by labelers. FDA cautions that a directory entry does not mean the agency has verified the submitted information or approved the product.
The practical reading is narrow: a number can help identify a listed product, but it cannot bear a claim that the medicine has passed an approval review. A seller placing the number beside an FDA logo risks leaving an impression broader than the underlying evidence supports.
Read the exact product claim
Approval language can shift between an ingredient and the finished formulation. A statement about an approved branded medicine should not be silently transferred to a different concentration, route, combination, or compounded preparation. The product being sold is the object of the question.
The useful comparison records the medicine name, formulation, and manufacturer or compounder, then examines what the cited agency source actually addresses. A seller page that combines these details loosely can appear well sourced while failing to connect its evidence to its own offering.
Keep documentation categories distinct
A pharmacy license, establishment registration, laboratory certificate, and NDC listing each serve different purposes. Putting them in one row of trust badges does not merge their meanings. The strongest public explanation names each document and states what it establishes.
For the ledger, S4 concerns disclosure that a compounded preparation is not FDA-approved. An NDC number cannot replace that disclosure. It also does not cure a contradictory approval claim elsewhere on the same product page. The appropriate finding describes both statements and their sources without converting a directory search into an independent quality judgment.
An absent result needs the same care. Search spelling, company names, and product identifiers can differ. Failure to find a number is not, by itself, evidence of counterfeiting. The sound conclusion is limited to what the checked record establishes.
Related standard: S4. Compounding disclosure. Evidence for individual companies appears in the seller ledger.
Related reading
Sources
Related findings
Oral and nasal peptides: does the evidence match the product?Evidence for a molecule does not automatically establish evidence for every product containing it. Match the exact formulation, route, strength and intended use before applying a study or an approval claim to an oral, sublingual or nasal offer.
How many sellers say the compounded drug is not FDA-approved?Fewer than the headline rate suggests. S4 has the highest pass rate of any criterion because a large block of sellers passes it by selling no compounded drugs at all; among the sellers the disclosure actually applies to, a real minority omits it.
Which peptides do the telehealth services actually sell?GLP-1 drugs lead, and sermorelin and NAD+ follow close behind. Several services list molecules whose compounding nomination was withdrawn, and a handful of sites call a product FDA-approved when no approved version of it is what they sell.
Medical records and prescription transfers are different requestsReceiving a copy of a medical record does not transfer a prescription or authorize another refill. Identify the clinical record holder for the records request, and ask the pharmacies or prescriber separately about any prescription action.